GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Veracyte Inc (NAS:VCYT) » Definitions » 5-Year Yield-on-Cost %

Veracyte (Veracyte) 5-Year Yield-on-Cost % : 0.00 (As of Apr. 26, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Veracyte 5-Year Yield-on-Cost %?

Veracyte's yield on cost for the quarter that ended in Dec. 2023 was 0.00.


The historical rank and industry rank for Veracyte's 5-Year Yield-on-Cost % or its related term are showing as below:



VCYT's 5-Year Yield-on-Cost % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 2.36
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of Veracyte's 5-Year Yield-on-Cost %

For the Diagnostics & Research subindustry, Veracyte's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Veracyte's 5-Year Yield-on-Cost % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Veracyte's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Veracyte's 5-Year Yield-on-Cost % falls into.



Veracyte 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Veracyte is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

Veracyte  (NAS:VCYT) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Veracyte 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Veracyte's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


Veracyte (Veracyte) Business Description

Traded in Other Exchanges
Address
6000 Shoreline Court, Suite 300, South San Francisco, CA, USA, 94080
Veracyte Inc is a genomic diagnostics company. It provides genomic diagnostic products and services to improve patient care against diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. The firm's product portfolio consists of products such as Afirma analysis, Percepta, Envisia, and others. The company derives its revenues from the Sale of Afirma analysis products.
Executives
Phillip G. Febbo officer: Chief Scientific & Med Officer C/O GENOMIC HEALTH, INC., 301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
John Leite officer: Chief Commercial Officer-CLIA 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Evan/ Fa Jones director C/O OPGEN, INC., 708 QUINCE ORCHARD ROAD, SUITE 205, GAITHERSBURG MD 20878
John L Bishop director
Muna Bhanji director C/O CYTOKINETICS, INCORPORATED, 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Bonnie H Anderson director, officer: President & CEO 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Karin Eastham director C/O BURNHAM INSTITUTE FOR MEDICAL RESEAR, 10901 N. TORREY PINES ROAD, LA JOLLA CA 92037
Giulia C Kennedy officer: Chief Scientific & Med Officer 338 MAIN STREET #26E, SAN FRANCISCO CA 94105
Eliav Barr director C/O VERACYTE, INC., 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Jens Holstein director C/O VERACYTE, INC., 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Marc Stapley officer: Chief Executive Officer 9885 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
Kevin K Gordon director 155 S LIMERICK RD, LIMERICK PA 19468
Jonathan Wygant officer: VP, Chief Accounting Officer 3750 TORREY VIEW COURT, SAN DIEGO X1 92130
Annie Mcguire officer: SVP, General Counsel C/O VERACYTE, INC., 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Rebecca Chambers officer: Chief Financial Officer 3052 ORCHARD DR., SAN JOSE CA 95134

Veracyte (Veracyte) Headlines

From GuruFocus